Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ibio Inc IBIO

Healthcare Biotechnology
iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu... see more

Recent & Breaking News (NYSEAM:IBIO)

iBio Announces Issuance of U.S. Patent Covering AI-Engineered Epitope Discovery Engine

GlobeNewswire January 5, 2023

iBio Announces Closing of $3.5 Million Underwritten Public Offering

GlobeNewswire December 9, 2022

iBio Announces Pricing of $3.5 Million Underwritten Public Offering

GlobeNewswire December 6, 2022

iBio Announces Proposed Underwritten Public Offering

GlobeNewswire December 6, 2022

iBio to Participate in the JMP Securities Hematology and Oncology Summit

GlobeNewswire December 6, 2022

iBio® to Showcase the RubrYc® Discovery Engine During Poster Presentations at Antibody Engineering & Therapeutics Conference 2022

GlobeNewswire December 5, 2022

iBio Announces CEO Departure

GlobeNewswire December 2, 2022

iBio Accelerates Transformation to AI-Powered Biotech

GlobeNewswire November 3, 2022

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

GlobeNewswire September 27, 2022

iBio Acquires RubrYc Therapeutics' AI Drug Discovery Platform and Pipeline

GlobeNewswire September 21, 2022

iBio Provides Update on Development of Next-Gen COVID-19 Vaccine Candidate

GlobeNewswire August 16, 2022

iBio to Participate in the H.C. Wainwright Global Investment Conference

GlobeNewswire May 18, 2022

iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 12, 2022

iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer

GlobeNewswire May 9, 2022

iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022

GlobeNewswire May 5, 2022

iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants

GlobeNewswire May 2, 2022

iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference

GlobeNewswire March 11, 2022

iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire February 14, 2022

iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022

GlobeNewswire February 7, 2022

iBio Announces Progression of Vaccine Program for Multi-Variant COVID-19 Disease

GlobeNewswire January 26, 2022